{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiehrq6jyzxungy7nsgxajxftnekvxk6tl4h2h6ubbvq34lg3lyqwy",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mfmwp2wo3zf2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreia3av6awum56fmsrrhdpzt7aza56i2b23fxf56diaivhf37u6t2ea"
    },
    "mimeType": "image/jpeg",
    "size": 60379
  },
  "path": "/2026/02/24/pharma-opposition-medicare-drug-price-pilot-programs-strategy-emerges/?utm_campaign=rss",
  "publishedAt": "2026-02-24T17:57:19.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "Insurance",
    "Pharma",
    "Politics",
    "biotechnology",
    "CMS",
    "Congress",
    "Donald Trump",
    "Drug prices",
    "Medicare",
    "Pharmaceuticals",
    "Policy",
    "STAT+"
  ],
  "textContent": "Comments opposing Medicare's efforts to lower U.S. drug prices provide a roadmap to potential legal challenges ahead.",
  "title": "STAT+: Drugmakers lay out their legal arguments against Trump’s drug pricing experiments",
  "updatedAt": "2026-02-24T18:16:07.000Z"
}